Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats

Life Sci. 2012 May 22;90(19-20):721-7. doi: 10.1016/j.lfs.2012.03.008. Epub 2012 Apr 1.

Abstract

Aims: In the present study, we explored the hypothesis that initiation of PH involves the upregulation of monocyte chemoattractant protein-1 (MCP-1) in acute PTE. We evaluated the effects of resveratrol and the role of p38 mitogen-activated protein kinase (MAPK) in this process.

Main methods: A rat model of acute PTE was established by infusion of an autologous blood clot into the pulmonary artery through a polyethylene catheter. Rats were randomly divided into 1, 4, and 8 hour time groups. Resveratrol, C1142 (a rodent chimeric mAb that neutralizes rat MCP-1) or SB203580 (a p38MAPK specific inhibitor) was administered to the animals beginning 1 h prior to the start of the acute PTE protocol. At each time point, the mean pulmonary artery pressure (mPAP), mRNA and protein expressions of MCP-1 were measured. The phosphorylation of p38 MAPK (p-pMAPK) was also detected.

Key findings: Acute PTE elicited significant increases in mean pulmonary artery pressure (mPAP), and up-regulated the expression of monocyte chemoattractant protein-1 (MCP-1) and phosphorylation of p38 mitogen-activated protein kinase (p-p38 MAPK). Administration of C1142 markedly reduced mPAP. Furthermore, pre-treatment of rats with resveratrol significantly reduced mPAP and down-regulated the expression of MCP-1, which was associated with robustly suppressed acute PTE-induced p-p38MAPK expression.

Significance: These findings suggested that MCP-1 was involved in the formation of acute PTE-induced PH, and resveratrol down-regulated the expression of MCP-1 by inhibiting acute PTE-induced p-p38MAPK activation, which contributed to the decrease in PH.

MeSH terms

  • Animals
  • Blotting, Western
  • Chemokine CCL2 / antagonists & inhibitors*
  • Chemokine CCL2 / biosynthesis
  • Chemokine CCL2 / physiology
  • Down-Regulation / drug effects
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Fluorescent Antibody Technique
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / drug therapy*
  • Imidazoles / pharmacology
  • Immunohistochemistry
  • Indicators and Reagents
  • Male
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / drug therapy*
  • Pyridines / pharmacology
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Sprague-Dawley
  • Real-Time Polymerase Chain Reaction
  • Resveratrol
  • Signal Transduction / drug effects*
  • Stilbenes / pharmacology*
  • Stilbenes / therapeutic use
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • p38 Mitogen-Activated Protein Kinases / biosynthesis
  • p38 Mitogen-Activated Protein Kinases / physiology

Substances

  • Chemokine CCL2
  • Enzyme Inhibitors
  • Imidazoles
  • Indicators and Reagents
  • Pyridines
  • RNA, Messenger
  • Stilbenes
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580
  • Resveratrol